Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Signs Plant Proteomics Research Deal with Syngenta

NEW YORK (GenomeWeb News) – Berlin-based biotech-firm Caprotec Bioanalytics said today that it has entered a research agreement with Syngenta to profile the interactions of one of Syngenta's active compounds with the proteome of certain relevant plant systems.

The companies will use Caprotec's Capture Compound Mass Spectrometry technology, with Syngenta covering the research costs and providing Caprotec with success-based milestone payments. Further financial details were not disclosed.

Caprotec's CCMS technology uses capture compounds to reversibly bind target proteins on the basis of small molecule-protein interactions. The captured proteins are then pulled out and analyzed via mass spectrometry.

The deal is the second that Caprotec has announced in recent weeks for use of its CCMS technology in agri-bio research. Last month the company announced a research collaboration with Bayer CropScience using CCMS to identify and study an agrochemical target.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.